What is Alosetron Hydrochloride used for?

Alosetron Hydrochloride, commonly marketed under the trade name Lotronex, is a pharmaceutical used primarily for the treatment of severe diarrhea-predominant irritable bowel syndrome (IBS-D) in women. Developed by GlaxoSmithKline, it is a selective serotonin 5-HT3 receptor antagonist. This drug is unique in its class, specifically targeting the enteric nervous system to modulate the gut's motility, secretion, and pain perception. It has undergone rigorous clinical trials and research to validate its efficacy, resulting in its approval by the Food and Drug Administration (FDA) in 2000. However, due to severe side effects, it was temporarily withdrawn from the market later that year before being reintroduced in 2002 under a restricted prescribing program.

Alosetron Hydrochloride exerts its effects by blocking the 5-HT3 receptors located on the neurons in the gastrointestinal tract. Serotonin, a neurotransmitter, plays a significant role in the regulation of bowel function and sensation. By antagonizing these receptors, Alosetron Hydrochloride inhibits the increased colonic transit and secretion of fluids that are typically seen in IBS-D. Moreover, the drug helps in alleviating visceral pain, making it highly effective in providing relief to patients suffering from this debilitating condition.

 

Researching Alosetron Hydrochloride beyond the basics?

Synapse Hiro LS Researcher, the Synapse AI Insight Engine, is built to accelerate biopharma decisions. Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence. Explore Alosetron Hydrochloride with Hiro LS Researcher →

The administration of Alosetron Hydrochloride is oral, commonly prescribed in the form of tablets. Typically, the recommended starting dose is 0.5 mg taken twice daily, with or without food. The onset of action might vary among individuals, but patients could notice an improvement in their symptoms within the first week of treatment. If well tolerated, the dose can be increased to 1 mg twice daily. It is crucial for patients to adhere to the prescribed dosage and consult their healthcare provider before making any changes. Notably, the drug is only approved for use in women suffering from severe IBS-D who have not responded to conventional therapies due to concerns about serious side effects.

As with any medication, Alosetron Hydrochloride has a profile of potential side effects. The most common adverse effects include constipation, which can be severe and lead to complications like ischemic colitis, a condition characterized by reduced blood flow to the intestines. Due to this risk, the FDA mandates that physicians and patients engage in a risk management program before starting treatment. Other side effects might include abdominal pain, nausea, and gastrointestinal discomfort.

Contraindications for the use of Alosetron Hydrochloride include patients with a history of chronic constipation, intestinal obstruction, Crohn's disease, ulcerative colitis, or severe hepatic impairment. Additionally, patients with a history of ischemic colitis or other serious complications related to constipation should avoid this medication. It is also not recommended for use in men or children, as the safety and efficacy in these populations have not been established.

Furthermore, certain drug interactions may affect the efficacy or increase the risk of adverse effects when taking Alosetron Hydrochloride. Drugs that influence cytochrome P450 enzymes, specifically CYP3A4, CYP2C9, and CYP1A2, could potentially alter the metabolism of Alosetron. For example, the concomitant use of fluvoxamine, a potent CYP1A2 inhibitor, is contraindicated as it significantly increases the plasma concentration of Alosetron, elevating the risk of serious side effects. Other drugs that may interact include ketoconazole, clarithromycin, and other strong inhibitors of these enzymes. It is essential for patients to inform their healthcare provider of all medications, including over-the-counter drugs and supplements, to manage potential interactions effectively.

In conclusion, Alosetron Hydrochloride represents a significant advancement in the treatment of severe IBS-D in women, offering relief from symptoms that significantly impact the quality of life. However, its use requires careful consideration of the risks and benefits, strict adherence to prescribed dosages, and close monitoring for adverse effects. Through a collaborative approach between patients and healthcare providers, the therapeutic potential of Alosetron Hydrochloride can be maximized while minimizing the associated risks.

Continue your Alosetron Hydrochloride research with Synapse Hiro LS Researcher

This article provides an overview. For a broader research view, use Synapse Hiro LS Researcher—the Synapse AI Insight Engine—to search across drugs, targets, indications, clinical trials, literature, organizations, news, deals, and competitor signals. Ask any biopharma research question in natural language.

Questions to explore:

• What approved and investigational uses have been reported for Alosetron Hydrochloride?
• What is the mechanism of action of Alosetron Hydrochloride, and which targets or pathways are involved?
• Which clinical trials are evaluating Alosetron Hydrochloride, and what outcomes have been reported?
• What patents, publications, and regulatory sources provide the latest evidence on Alosetron Hydrochloride?

Ask Synapse Hiro LS Researcher →

AI may make mistakes. Check important info.